| Document |
Document Title |
|
WO/1992/006079A1 |
The present invention relates to novel fused ring analogs of nitrogen containing heterocycles, and specifically, to compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, x, y, and z and m are defined as below. These novel com...
|
|
WO/1991/013870A1 |
Mercaptoacyl aminolactam inhibitors of endopeptidases of formula (I), wherein Y is -(CHR5)n(CR3R4)- or -(CR3R4)pX(CR3R4)q-, wherein two substituents selected from the group consisting of R3, R4 and R5, can form a benzene, cyclopentane or...
|
|
WO/1991/005549A1 |
Novel benzoheterocyclic compounds of formula (I), wherein R?1¿ is H, halogen, alkyl, optionally substituted amino, alkoxy; R?2¿ is H, halogen, alkoxy, phenylalkoxy, OH, alkyl, optionally substituted amino, carbamoyl-alkoxy, optionally ...
|
|
WO/1991/003467A1 |
Compounds of formula (I), wherein R1, R2, R3, R4, X, m, n, o, p, q and r are as defined below. The compounds are memory enhancing cholinesterase inhibitors useful in enhancing memory, novel intermediates used in their synthesis, and anal...
|
|
WO/1991/000273A1 |
Cyclic anthranilic acid derivatives of general formula (I) and acid addition salts and alkali salts thereof, useful for treating rheumatism, autoimmune diseases and metabolic bone diseases, wherein R1, R2 and R3 may be the same of differ...
|
|
WO/1990/015797A2 |
The invention relates primarily to quaternized compounds having formula (I) wherein n and n' are each independently integers having a value of from 1 to 25; p is an integer having a value of from 1 to 4; Y and Y' are each independently H...
|
|
WO/1990/003365A1 |
This invention relates to quaternary compounds having formula (I), wherein W- is an anion; m and n are integers having a value of from 1 to 4; R is alkylene having from 3 to 8 carbon atoms; R1 is a radical having from 8 to 25 carbon atom...
|
|
WO/1989/010115A1 |
A composition comprising an aqueous hair coloring, bleaching, reducing, oxidizing or permanent structure altering formulation and a conditioning amount of a quaternized compound having formula (I), wherein M is an integer having a value ...
|
|
WO/1989/010358A1 |
The invention relates primarily to quaternized compounds having formula (I), wherein m is an integer having a value of from 1 to 4; R is alkylene having from 3 to 8 carbon atoms and is optionally substituted with C1 to C4 alkyl; R1, R2 a...
|
|
WO/1989/002735A1 |
This invention provides compositions comprising a physiologically-active agent and a compound represented by general formula (I), wherein X may represent sulfur, oxygen or 2 hydrogen radicals; Y may represent -CH2-, -NH- or oxygen; n and...
|
|
WO/1988/007527A1 |
The amino-9,10-secosteroids of formula (I) of the present invention contain an amino group attached to the terminal carbon atom of the C17-side chain and are useful as pharmaceutical agents for treating a number of conditions including s...
|
|
WO/1988/002626A1 |
Method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation comprising topically administering with said systemic age...
|
|
WO/1987/005603A1 |
A compound having formula (I), wherein R1 is the esterification residue of an alcohol (R1-OH) having from 1 to 8 carbon atoms; R2 is a substituted or unsubstituted aryl, cycloalkyl or alkyl group having from 1 to 8 carbon atoms; R3 is H ...
|
|
WO/1987/005289A1 |
A biarylic coupling method, the ruthenium catalyst for its implementation and the new compound resulting therefrom. The biarylic coupling method according to the invention is characterized in that the biarylic precursors are cycled in th...
|
|
WO/1987/004706A1 |
Compositions comprising a compound having structural formula (I), wherein X may represent sulfur or two hydrogen atoms; R' is H or a lower alkyl group having 1-4 carbon atoms; m is 2-6; n is 0-18 and R is -CH3, formula (II) or formula (I...
|
|
WO/1986/005784A1 |
Compounds represented by general formula (I) (wherein R1 and R2, which may be the same or different, each represents hydrogen or an organic residue via a carbon atom or -SO2-, X represents (II), (III), (IV), (V), (wherein R4 represents h...
|
|
JP2024066036A |
[Problem] In the production of amide compounds using ketones as raw materials, it is necessary to remove and reduce water in the solvent between the oxime formation process and the amidation process by Beckmann rearrangement. It was diff...
|
|
JP7436370B2 |
Disclosed are a quaternary ammonium salt compound, a preparation method therefor and a use thereof. Provided is a novel structural compound as shown in formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, ...
|
|
JP2024504312A |
The present invention relates to a method for purifying laurolactam, and more particularly to a method for purifying laurolactam with high purity and almost no impurities. The present invention is a method for purifying laurolactam from ...
|
|
JP2023179471A |
To provide a novel alginic acid derivative or a novel crosslinked alginic acid, and production methods therefor.The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked ...
|
|
JP2023550492A |
The present invention comprises the steps of: a) synthesizing cyclododecanone oxime to laurolactam by Bechmann rearrangement under a catalyst; b) mixing the laurolactam synthesized in step a) with a good solvent; c) mixing the laurolacta...
|
|
JP7350940B2 |
The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an ...
|
|
JP2023538842A |
[Solution] The present invention contains monomeric diphenylmethane diisocyanate (MDI) as component (q1), and an amide with a molecular weight of less than 200 g/mol as component (q2), the total of components (q1) and (q2) being 100% by ...
|
|
JP2023113639A |
To provide novel bis-octahydrophenanthrene carboxamides effective for treating diseases and disorders associated with the liver X receptor by forming protein (e.g., antibody) drug conjugates.The invention provides a compound of Formula I...
|
|
JP2023516965A |
The present disclosure provides a class of conjugates of general formula (X), a class of TLR9 agonist derivatives such as formulas (I), (XX) and (XXI), STING, as defined herein. Certain diastereomers of agonists, a class of STING agonist...
|
|
JP2023508872A |
A method for producing N-vinyl compounds by homogeneous catalysis, comprising reacting acetylene with at least one nitrogen atom in the liquid phase in the presence of a ruthenium complex containing at least one phosphine as a ligand (Ru...
|
|
JP7231740B2 |
The present invention relates to a laurolactam preparation method and synthesis apparatus, and epoxidation and a rearrangement reaction are performed in the conversion of cyclododecene into cyclododecanone so that the preparation method ...
|
|
JP2023504265A |
The present invention comprises the steps of a) synthesizing cyclododecanone oxime as laurolactam by Bechmann rearrangement under a catalytic system, and b) mixing laurolactam synthesized in step a) with a good solvent. , a step of remov...
|
|
JP7185624B2 |
Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than...
|
|
JP7128121B2 |
Applicants have developed an amplification system and methodology for IHC and ISH staining that utilizes “click chemistry” to covalently bind reporter molecules to tissue.
|
|
JP2022537543A |
The invention disclosed herein relates to compounds, combinations, kits and methods of their use for use in bioorthogonal release reactions. In particular, compounds, combinations and kits of the invention can be used to achieve rapid an...
|
|
JP7121024B2 |
One aspect of the present invention provides a compound in which a functional group capable of binding to a globulin Fc region or a physiologically active polypeptide is introduced at one end of a non-peptidic polymer and a functional gr...
|
|
JP2022120170A |
To provide a method for producing a callyspongiolide derivative to, among other things, treat various forms of cancer.A compound of the formula (I) is synthesized by Sonogashira coupling of an acetylenic compound with a corresponding vin...
|
|
JP2022090290A |
To provide a light source device for photochemical reaction having a heat sink made of an aluminum alloy resistant to corrosion, a photochemical reaction device and method using the light source device, and a method for producing lactam ...
|
|
JP2022527731A |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compounds, compositions, methods and kits of the present invention are useful in the treatment of pain, itch and neurological inf...
|
|
JP2022518599A |
The present invention relates to a quaternary ammonium salt compound and a method and use thereof, and belongs to the field of chemical medicine. The present invention provides a compound represented by Formula I, or a pharmaceutically a...
|
|
JP2022041072A |
To provide an inhibitor effective against IMP type metallo-β-lactamase.The present invention discloses a compound represented by the following formula [R1 and R4 each denote an optionally substituted, C1-10 alkyl group, C2-10 alkenyl gr...
|
|
JP6952974B2 |
To provide a novel method for producing an amide compound which does not require severe reacting conditions without directly using hydroxylamine and its derivative.There is provided a method for producing an amide compound which comprise...
|
|
JP6895935B2 |
Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as ph...
|
|
JP2021014406A |
To provide a compound that is highly water-soluble and has a vasopressin V2 receptor antagonistic action, which is particularly suitable for parenteral injections, and to provide a pharmaceutical containing said compound.Provided are a c...
|
|
JP2020121252A |
To provide a photoreaction device achieving more desirable light irradiation with higher light transmittance by further suppressing light reflection in a light irradiation path between a light-emitting diode light source and a target pho...
|
|
JP2020520926A |
Provided herein are compounds, compositions for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamide and protein (eg, antibody) drug conjugates thereof. And the met...
|
|
JP6716568B2 |
The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or a salt thereof, and processes for synthesizing the same.
|
|
JP6636031B2 |
and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and meth...
|
|
JP6610687B2 |
A power supply device, a photochemical reaction device and method in which the power supply device is used, and a lactam production method in which the photochemical reaction method is used, the power supply device being characterized by...
|
|
JP6567332B2 |
The invention relates to a method for preparing lactames, according to which a photonitrosation of a cycloalkane is carried out using nitrosyl chloride (NOCI). According to the invention, said photonitrosation is carried out by means of ...
|
|
JP6559251B2 |
Methods for producing lactams from oximes by performing a Beckmann rearrangement using a hierarchical porous aluminophosphate catalyst having interconnected microporous and mesoporous networks are provided. Exemplary catalysts include a ...
|
|
JP2019520427A |
The present disclosure includes high-purity compounds having CCR5 and / or CCR2 antagonistic activity, or salts thereof, high-purity intermediates therefor, and methods for synthesizing the compounds. The present disclosure is highly pur...
|
|
JP2019517474A |
As used herein, compounds of formulas (I)-(III) (or pharmaceutically acceptable salts thereof, polymorphs, prodrugs, solvates, or clathrates thereof), and in particular various types, are used. Methods for making and using compounds of f...
|
|
JP6513823B2 |
Disclosed herein is an efficient, economical, industrially advantageous, straight-through process for the preparation of cyclic amides, also referred as lactams, in substantially pure form and high yield, from the corresponding cyclic ke...
|
